MDxHealth Announces Proposed Transition to a Sole Listing of Shares on Nasdaq and Convenes an Extraordinary General Shareholders Meeting - Seite 2

Michael K. McGarrity, CEO of mdxhealth, commented: "A key priority for us has been to create a more attractive and efficient trading mechanism for our global investors and stakeholders and to support increasing interest from new investors, while reducing our operating costs. We believe the transition to trade exclusively on the Nasdaq accomplishes this objective. This is an exciting time for mdxhealth, and we look forward to expanding our shareholder base as we continue to execute and drive growth as a leading precision diagnostics company."

For further information and details regarding the proposed Transaction, reference is made to the dedicated web page which can be found on the Company's website, which contains (among other things) (i) a Special Report describing the proposals that will be submitted to the Company's extraordinary general shareholders' meeting, (ii) a letter from the chair of the board of directors summarizing the Transaction, and (iii) frequently asked questions (FAQs) providing context and technical details with respect to the Transaction. This web page and the FAQs will be kept up-to-date as and when necessary.

Extraordinary Shareholders Meeting

In order to implement the Transaction, it will be necessary for the Company’s shareholders to approve the Share Consolidation and the De-Listing. In view thereof, the board of directors hereby convenes an extraordinary general shareholders’ meeting to be held on November 3, 2023 at 3:00 p.m., Belgian time, to seek required shareholder approvals.

The items on the agenda of the extraordinary general shareholders' meeting include the approval of the proposed Share Consolidation and De-Listing, as well as a number of technical amendments to the Company's articles of association that allow for the De-Listing.

In order to participate in the extraordinary general shareholders’ meeting of the Company, the holders of securities issued by the Company must comply with article 7:134, §2, first indent of the Belgian Companies and Associations Code and the articles of association of the Company, and fulfill the formalities described in the convening notice. The convening notice, forms and other documents relating to the extraordinary general shareholders’ meeting can be found on the dedicated web page which can be found on the Company's website.